|
Search
Collections
Benchmarks
Upload document
Product
Atazanavir + Cobicistat
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
1 clinical trial
1 indication
Indication
Healthy Participants
Clinical trial
An Open-Label, Randomized, Single-Dose, 3-Treatment, 3-Period, 3-Sequence, Crossover Design, Relative Bioavailability Study Comparing the Pharmacokinetics of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations (ATV and COBI Oral Mini-tablets; 300 mg and 150 mg, Respectively) and the Coadministration of the Individual Reference Products (REYATAZ [Atazanavir Oral Powder] and TYBOST [Cobicistat Oral Tablet]; 300 mg and 150 mg, Respectively) in Healthy Adults Under Fed Conditions
Status: Completed
, Estimated PCD: 2022-07-05